Enteromycetin Suspension, containing Chloramphenicol 125mg per 5ml, is a broad-spectrum antibiotic indicated for the treatment of various bacterial infections, particularly those caused by susceptible strains of Gram-positive and Gram-negative organisms. Chloramphenicol acts by inhibiting bacterial protein synthesis through binding to the 50S ribosomal subunit, thereby preventing peptide bond formation and bacterial growth. This formulation is primarily used in the management of enteric infections such as typhoid fever, paratyphoid fever, and other systemic infections where oral therapy is appropriate. Enteromycetin Suspension is suitable for pediatric and adult patients who require an effective oral antibiotic with good bioavailability. The dosage should be individualized based on the severity of infection, patient age, weight, and renal function, with careful adherence to prescribed regimens to minimize resistance development. Common adverse effects may include gastrointestinal disturbances, hypersensitivity reactions, and rare but serious hematological effects such as aplastic anemia and bone marrow suppression; therefore, regular monitoring of blood counts is recommended during prolonged therapy. Enteromycetin Suspension should be used with caution in patients with pre-existing hematologic disorders or hepatic impairment. It is contraindicated in patients with known hypersensitivity to chloramphenicol or its components. Proper storage conditions should be maintained to preserve the suspension’s efficacy and stability.